Fly News Breaks for September 9, 2019
Sep 9, 2019 | 07:22 EDT
Cantor Fitzgerald analyst Charles Duncan started Adamas Pharmaceuticals with a Neutral rating and $8 price target. The lack of conviction in Gocovri sales growth is priced into the stock, but positive sales trends in the next 6-12 months are "needed to facilitate a turn in this battleground story," Duncan tells investors in a research note.
News For ADMS From the Last 2 Days
There are no results for your query ADMS